

# Systemic Lupus Erythematosus - Pipeline Review, H1 2020

<https://marketpublishers.com/r/SA551E81228EN.html>

Date: May 2020

Pages: 717

Price: US\$ 2,000.00 (Single User License)

ID: SA551E81228EN

## Abstracts

Systemic Lupus Erythematosus - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H1 2020, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

'Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.'

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 35, 22, 1, 72, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).

The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Systemic Lupus

Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Systemic Lupus Erythematosus - Overview

Systemic Lupus Erythematosus - Therapeutics Development

Systemic Lupus Erythematosus - Therapeutics Assessment

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

Systemic Lupus Erythematosus - Drug Profiles

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2020

Systemic Lupus Erythematosus - Pipeline by ACEA Therapeutics Inc, H1 2020

Systemic Lupus Erythematosus - Pipeline by Akeso Inc, H1 2020

Systemic Lupus Erythematosus - Dormant Projects, H1 2020

Systemic Lupus Erythematosus - Discontinued Products, H1 2020

Systemic Lupus Erythematosus - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
ACEA Therapeutics Inc  
Akeso Inc  
Alpine Immune Sciences Inc  
Aluda Pharmaceuticals Inc  
Amgen Inc  
Apellis Pharmaceuticals Inc  
Apimeds Inc  
APT Therapeutics Inc  
Asahi Kasei Pharma Corp  
Astellas Pharma Inc  
AstraZeneca Plc  
Atlantic Bio Sci LLC  
Aurinia Pharmaceuticals Inc  
BellBrook Labs LLC  
Bio-Path Holdings Inc  
BioAegis Therapeutics Inc  
Biocon Ltd  
Biogen Inc  
Biotest AG  
Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc  
Bristol-Myers Squibb Co  
Capricor Therapeutics Inc  
Carna Biosciences Inc  
Cells for Cells SA  
Chipscreen Biosciences Ltd  
Chong Kun Dang Pharmaceutical Corp  
Cityll BV  
Corbus Pharmaceuticals Inc  
Corestem Inc  
CuraVac Inc  
Cyteir Therapeutics Inc  
Daewoong Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
Domainex Ltd  
Eli Lilly and Co  
Epsilon-3 Bio Ltd  
Ergon Pharmaceuticals LLC  
Exinda Therapeutics LLC  
F. Hoffmann-La Roche Ltd  
Galapagos NV  
Genentech Inc  
GeneScience Pharmaceuticals Co Ltd  
Genesen Co Ltd  
Genosco Inc  
Genovax Srl  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Good T Cells Inc  
HanAll Biopharma Co Ltd  
Hanmi Pharmaceuticals Co Ltd  
HemoGenyx LLC  
Ichnos Sciences Inc  
Idorsia Pharmaceutical Ltd  
IL-2Rx Inc  
Iltoo Pharma  
Implacate  
Immune Modulation Inc  
Immungenetics AG



ImmunoQure AG  
Immunwork Inc  
Immupharma Plc  
InnoCare Pharma Ltd  
Innovimmune Biotherapeutics Inc  
iSD Immunotech ApS  
Janus Biotherapeutics Inc  
JiangSu Qyuns Therapeutics Co Ltd  
Johnson & Johnson  
Jura Bio Inc  
K-Stemcell Co Ltd  
Kangpu Biopharmaceuticals Ltd  
Karyopharm Therapeutics Inc  
Kezar Life Sciences Inc  
Kine Sciences  
Kiniksa Pharmaceuticals Ltd  
Kyowa Kirin Co Ltd  
Lead Discovery Center GmbH  
MedAnnex Ltd  
MENTRIK Biotech LLC  
Merck & Co Inc  
Merck KGaA  
Millennium Pharmaceuticals Inc  
MorphoSys AG  
Mount Tam Biotechnologies Inc  
Nektar Therapeutics  
Neovacs SA  
Novartis AG  
Octagon Therapeutics Inc  
Omeros Corp  
Pfizer Inc  
Pharchoice Therapeutics Inc  
ProNoxis AB  
Provention Bio Inc  
Ra Pharmaceuticals Inc  
ReAlta Life Sciences Inc  
RedHill Biopharma Ltd  
Regen BioPharma Inc  
RemeGen Ltd

Resolve Therapeutics LLC  
Rheos Medicines Inc  
Sanofi  
Sareum Holdings Plc  
SBI Biotech Co Ltd  
Sengenics International Pte Ltd  
Shanghai GeneChem Co Ltd  
Shanghai Junshi Bioscience Co Ltd  
SinoMab Bioscience Ltd  
StingInn LLC  
Suzhou Sinovent Pharmaceuticals Co Ltd  
SynAct Pharma AB  
Taiho Pharmaceutical Co Ltd  
Takeda Pharmaceutical Co Ltd  
TherapyX Inc  
Tonix Pharmaceuticals Holding Corp  
UCB SA  
Viela Bio Inc  
Visterra Inc  
Voronoi  
Xencor Inc  
XTL Biopharmaceuticals Ltd  
ZyVersa Therapeutics Inc

## I would like to order

Product name: Systemic Lupus Erythematosus - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/SA551E81228EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SA551E81228EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970